KRAS G12D

South San Francisco, California, August 19, 2026 IDEAYA Biosciences has entered into a clinical collaboration with Genentech, a member...

BOSTON, July 28, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 203 Phase...

BOSTON, July 22, 2026 Verastem Oncology has announced that the first patient has been dosed in the TARGET-D 202...

WILMINGTON, Del., July 17, 2026 Incyte has announced that it will present six oncology studies, including four rapid oral...

REDWOOD CITY, Calif., June 24, 2026 Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio...

BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...

REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...